Publications
5674 Results
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Evaluation of CSF1R as a Prognostic and Predictive Biomarker in Colorectal Cancer
- Journal / Conference
- Society for Surgical Oncology Annual Meeting (March 27-29, 2025, Tampa, FL)
- Year
- 2025
- Research Committee(s)
- Palliative Care
- Study Number(s)
- S1316
Lessons Learned from SWOG S1316: Optimizing Surgical Trial Design for Malignant Bowel Obstruction
- Journal / Conference
- ASCO GU Cancers Symposium (Feb 13-15, 2025, San Francisco, CA)
- Year
- 2025
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-9346
Post hoc analysis of S9346 data
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/EA2186
Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT) - A randomized phase II study of Gemcitabine and NabPaclitaxel compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (NCT04233866)
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA), abstract 666
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/A021602
Efficacy and Safety of Cabozantinib for Advanced Gastrointestinal Neuroendocrine Tumors (NET) after Progression on Prior Therapy: A Subgroup Analysis of the Phase III CABINET Trial (Alliance A021602)
- Journal / Conference
- ASCO GU Cancers Symposium (Feb 13-15, 2025, San Francisco, CA), poster
- Year
- 2025
- Research Committee(s)
- Genitourinary
Approach to Treatment of Metastatic Hormone Sensitive Prostate (mHSPC) Cancer Among Cooperative Oncology Groups in North America
- Journal / Conference
- ASCO GU Cancers Symposium (Feb 13-15, 2025, San Francisco, CA), Trials in Progress, TPS887
- Year
- 2025
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1937
A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937- Updated Design
- Journal / Conference
- Society for Surgical Oncology Annual Meeting (March 27-29, 2025, Tampa, FL)
- Year
- 2025
- Research Committee(s)
- Palliative Care
- Study Number(s)
- S1316
Secondary analysis of SWOG S1316 shows improved survival with surgical intervention for malignant bowel obstruction
- Journal / Conference
- Society for Surgical Oncology Annual Meeting (March 27-29, 2025, Tampa, FL)
- Year
- 2025
- Research Committee(s)
- Palliative Care
- Study Number(s)
- S1316
Presence of Ascites in the Setting of Malignant Bowel Obstruction Leads to Shorter Survival
- Journal / Conference
- ASCO GU Cancers Symposium (Feb 13-15, 2025, San Francisco, CA), poster, abstract 268
- Year
- 2025
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-9346